FDA Approves Record-Breaking 59 Novel Drugs in 2018

FDA Approves Record-Breaking 59 Novel Drugs in 2018

The winners and losers from JPM 2019

The winners and losers from JPM 2019

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion

FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion